👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources.
Claim this profile →
✓ Verified
Trust score 98/100
Accepting new patients
Prof. Dr.
Prof. Dr. Adam Januszewski
Oncology
English
3,120+
Patients seen
10
Years in practice
11
Publications
1
Languages spoken
About
Dr. Adam Januszewski is a Consultant Medical Oncologist at St. Bartholomew’s Hospital, London, and serves as the Divisional Lead for Quality and Safety at Barts Cancer Centre. Specialising in thoracic oncology, he has a particular interest in personalised medicine, improving access to clinical trials, and early-stage lung cancer treatment. Dr. Januszewski adopts a patient-centred approach to delivering world-class cancer care, ensuring the highest standard of treatment for his patients.
With expertise in clinical trials and translational research, Dr. Januszewski is the chief investigator on international Phase 2 and 3 clinical trials. He plays an active role in shaping national cancer care policies and practices, holding positions on several influential committees, including the British Thoracic Oncology Group (BTOG) steering committee, the UK Lung Cancer Coalition (UKLCC), the Cancer Research UK (CRUK) regimen-specific consent form steering committee, and performing NICE technology appraisals.
Dr. Januszewski was awarded a PhD in Genomic Medicine from Imperial College London in 2019 while working as a research fellow at the Royal Marsden Hospital. He also holds a postgraduate diploma in cancer studies from the Institute of Cancer Research (2014) and a Bachelor of Science from Imperial College School of Medicine (2006). Over the course of his career, he has authored numerous book chapters, scientific publications, and has presented original research at international conferences, contributing significantly to the field of thoracic oncology.
With expertise in clinical trials and translational research, Dr. Januszewski is the chief investigator on international Phase 2 and 3 clinical trials. He plays an active role in shaping national cancer care policies and practices, holding positions on several influential committees, including the British Thoracic Oncology Group (BTOG) steering committee, the UK Lung Cancer Coalition (UKLCC), the Cancer Research UK (CRUK) regimen-specific consent form steering committee, and performing NICE technology appraisals.
Dr. Januszewski was awarded a PhD in Genomic Medicine from Imperial College London in 2019 while working as a research fellow at the Royal Marsden Hospital. He also holds a postgraduate diploma in cancer studies from the Institute of Cancer Research (2014) and a Bachelor of Science from Imperial College School of Medicine (2006). Over the course of his career, he has authored numerous book chapters, scientific publications, and has presented original research at international conferences, contributing significantly to the field of thoracic oncology.
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Prof. Dr. Adam Januszewski
Education & training
-
2006–2012 MD · Medicine and Surgery
-
2012–2016 Residency · Oncology
-
2016–2017 Fellowship · Subspecialty training
Career & appointments
-
2016-09–2017-08 Junior consultant
Licenses & insurance
Medical licenses
— Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
Generali Healthcare · 1,000,000 EUR coverage
· No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 1,506 |
| Annual physical exam | 99395 | 308 |
| Vaccination administration | 90471 | 1,036 |
| Minor procedure (skin) | 17110 | 2,867 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 90 min | in_clinic | 270.00 EUR |
| Minor procedure (skin) | 60 min | in_clinic | 360.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 4 · i10: 14
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.9522/euroclin.2025.0 · PMID: 30433276 · cited by 34
-
European registry analysis of Oncology outcomes
DOI: 10.4691/euroclin.2024.1 · PMID: 38616629 · cited by 32
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.3906/euroclin.2023.2 · PMID: 31538333 · cited by 134
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
- 🏆 Young Investigator Award · European Society · 2023 · international
Society memberships
- WONCA Europe — Family Doctors — Member · since 2017
- national college of family doctors — Member · since 2017
- European Union of Medical Specialists (UEMS) — Member · since 2017
Patient reviews
- Bedside Manner
- 5.00
- Knowledge
- 5.00
- Wait Time
- 4.75
- Staff Friendliness
- 5.00
- Ease Of Appointment
- 4.90
- Value For Money
- 4.92
- Would Recommend Pct
- 99
-
★ 5 verified visit
“Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”
-
★ 5 verified visit
“Took time to listen and reviewed all my previous results. I would absolutely recommend.”
-
★ 4 verified visit
“Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · adam.januszewski@euroclinics.example
- Accepted intl insurance
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
